We would like to thank you for your continuing support of the National Pregnancy Registry for Atypical Antipsychotics (NPRAA) at the Center for Women’s Mental Health at Massachusetts General Hospital. We are grateful for all the referrals made to the Registry as our numbers continue to grow every day. Given the Registry’s successful enrollment, we are pleased to announce our plan to release preliminary data at an upcoming conference in June, the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.

Our Center is still actively recruiting participants to the NPRAA. It is our hope that with continuing enrollment we will be able to report on not only the reproductive safety of atypical antipsychotics as a class, but also on the safety of individual medicines. Subjects eligible to participate in the Registry include ANY PREGNANT WOMAN. While we continue to enroll women exposed to atypical antipsychotics during pregnancy, we are also seeking subjects to participate in our CONTROL group. The control group includes any woman who is pregnant and who has NOT taken an atypical antipsychotic during pregnancy. Participation includes three brief phone interviews over a period of approximately 8 months, depending on when in pregnancy the woman enters the study.

Please keep in mind that the Registry’s ongoing success relies heavily on healthcare provider referrals and individual patient interest. For referrals to the NPRAA or to enroll, please call our Registry toll-free at 1-866-961-2388. Subjects wishing to enroll can now do so through our website by filling out this online interest form. We also encourage you to visit the Registry website www.womensmentalhealth.org/pregnancyregistry to learn more about the study. Please do not hesitate to contact us by phone at 1-866-961-2388 or by email at registry@womensmentalhealth.org if you have any questions.